Review Article

Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease

Table 5

Comparison of findings on costs of PD in selected studies.

AuthorCountry/RegionYearDesignCosts studiedPerspectiveValue/year
US
Comments

Yoritaka et al. [40]Japan2016715SPODS5,828Direct cost
Martínez-Martin et al., [44]Spain2015174PO/BUD/IS13,720.24/year 4Magnitude of disease and quality of life
Tamás et al. [39]Hungary2014110PE/BUD/I/OOPS/CH6,831Costs of illness and quality of life
Kowal et al. [22]USA2013630,000PED/IS22,800Economic load current and projected (by 2050) in the USA
Zhao et al. [19]Singapore2013195PE/MK/BUD/IS68,519 (over the lifetime period)Cost of illness
Johnson et al. [41]USA20131,151RED/ICS43,506 PDINST (cohort)Cost of illness x several cohorts
Bhattacharjee and Sambamoorthi [29]USA2013350RED/OOPS15,404Cost of illness/over expenditure associated with PD
Kaltenboeck et al. [23]USA201225,577REDG78,042 (ambulatory pac. PD)Survival rates and costs of patients of health programs
Bach et al. [43]Germany20121,449PED/IG6.00 (2190) to 12.69 (4631.85)Cost of illness/drugs/comorbidities
Lökk et al. [25]Sweden20124,163PE/REDS9,333Cost of illness/drugs
Johnson et al. [20]USA2011278POIS/CH/CS569,393 (45 years), 188,590 (55), 35,496 (65), 2,451 (75) (from 40 to 79 years)Indirect costs
Jennum et al. [26]Denmark201113,400RE/POD/IS7,763Cost of illness
Zhao et al. [38]Singapore2011195PE/BUD/I/OOPS10,129Cost of illness
von Campenhausen et al. [45]Europe (6 countries)2011486PE/RE/BUD/I/OOPS2,968 to 11,124Cost of illness
Winter et al. [30]Italy201070PO/BUD/I/OOPS19,574Cost of illness/drugs
Winter et al. [46]Germany2010145PO/PE/BUD/I/OOPG22,763Cost of illness
Winter et al. [47]Germany2010145/133PE/RED/IS21,138 to 35,864Cost of illness
Winter et al. [32]Czech Rep.2009100PE/RE/BUD/IS/CH/P12,483Cost of illness
Winter et al. [37]Russia2009100PE/PO/BUD/IS/CH5,935Cost of illness
Vargas et al. [42]Brazil2008144PE/PO/BUINNANAResource use X incapacity
McCrone et al. [33]UK2007175PE/RED/OOPCS/P19,861Cost of illness
Leibson et al. [35]USA200692PE/REDNAUnclearCost of illness per groups
Ragothaman et al. [36]India2006175PE/PODS707Cost of illness/direct costs
Wang et al. [48]China2006190PE/RE/BUD/IS925Cost of illness
Vossius et al. [31]Germany/Norway2006438PE/RE/PODS2,389 (Germany), 1,620 (Norway)Cost of PD drugs
Noyes et al. [27]USA2006717PE/RED/OOPS/P18,528Cost of illness/drugs/medicare
Cordato et al. [28]Australia200612PE/POD/IS5,380Cost of illness
Huse et al. [24]USA200520,016PE/REDCS10,037Cost of illness
Spottke et al. [34]Germany2005145PE/POD/I/OOPS/G/P22,723 ± 28,297Cost of illness
Cubo et al. [21]Spain200523,417REInt.GNAYears of life lost

Notes: SPO = semiprospective; PO = prospective; BU = bottom-up; PE = prevalent, MK = Markov; RE = retrospective; D = direct cost; I = indirect cost; OOP = out-of-pocket; Int. = intangible; S = society; CH = human capital; CS = insurance companies; G = government; NA = not applicable; P = patient; PDINST = patients with PD institutionalized; Medicare = USA health care.